Ding, Han

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 342

Epidemiology of worldwide spinal cord injury: a literature review

Kang, Y., Ding, H., Zhou, H., Wei, Z., Liu, L., Pan, D., & Feng, S. (2017) · Journal of Neurorestoratology

Spinal Cord Injury ResearchTrauma and Emergency Care Studies

Cited by 315

A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects

Cheung, D., Fong, A., Ding, H. T., Cabanski, C. R., Wang, J., Chen, Y., Bush, J., Harris, J. M., & Pan, L. (2021) · Pulmonary Pharmacology & Therapeutics

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 6